期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌治疗原则、现状和进展 被引量：9

原文传递
导出
摘要 临床上根据肿瘤的分子特征、病理和分期来决定肺癌治疗策略。实体瘤病情程度大致分为可行根治手术、局部晚期和转移性（主要指血行转移）肿瘤三类。肿瘤驱动基因与临床的关系明晰，使非小细胞肺癌（non-smallcelllungcancer，NSCLC）的治疗模式发生了革命性变化，患者生存得到延长。
作者 于鹏 王跃辉 祝毓琳 马进元 朱步东
机构地区 青岛市即墨市人民医院肿瘤科 吉林省四平市肿瘤医院 北京大学肿瘤医院暨北京市肿瘤防治研究所日间病房 承德钢铁集团有限公司职工医院二内科
出处 《中华临床医师杂志（电子版）》 CAS 2013年第18期19-24,共6页 Chinese Journal of Clinicians(Electronic Edition)
关键词 非小细胞肺癌 治疗原则 分子特征 根治手术 病情程度 血行转移 局部晚期 肿瘤
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献43

  • 1Guyatt GH,Oxman AD,Vist GE. for the GRADE Working Group.GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J].British Medical Journal,2008.924-926.
  • 2Goss G,Shepherd FA,Laurie S. A phase I and pharmacokinetic study of daily oral cediranib,an inhibitor of vascular endothelial growth factor tyrosine kinases,in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer:a study of the National Cancer Institute of Canada Clinical Trials Group[J].European Journal of Cancer,2009.782-788.
  • 3Karp DD,Paz-Ares LG,Novello S. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated,locally advanced,or metastatic non-small-cell lung cancer[J].Journal of Clinical Oncology,2009.2516-2522.
  • 4Shaw AT,Kim DW,Nakagawa K. Phase Ⅲ study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer(NSCLC)(abstract LBA1 PR)[A].2012.
  • 5Takahashi T,Sonobe M,Kobayashi M. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene[J].Annals of Surgical Oncology,2010,(3):889-897.doi:10.1245/s10434-009-0808-7.
  • 6Mino-Kenudson M,Chirieac LR,Law K. A novel,highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry[J].Clinical Cancer Research,2010.1561-1571.
  • 7Herbst RS,Prager D,Hermann R. TRIBUTE:A phase Ⅲ trial of erlotinib(OSI-774)combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer[J].Journal of Clinical Oncology,2005.5892-5899.
  • 8Gatzemeier U,Pluzanska A,Szczesna A. Phase Ⅲ study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer:the Tarceva Lung Cancer Investigation Trial[J].Journal of Clinical Oncology,2007,(12):1545-1552.doi:10.1200/JCO.2005.05.1474.
  • 9Fukuoka M,Wu YL,Thongprasert S. Biomarker analyses and final overall survival results from a phase Ⅲ,randomized,open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS)[J].Journal of Clinical Oncology,2011.2866-2874.
  • 10Mitsudomi T,Morita S,Yatabe Y. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label,randomised phase 3 trial[J].Lancet Oncology,2010,(2):121-128.doi:10.1016/S1470-2045(09)70364-X.

二级参考文献24

  • 1Harris L,Fritsche H,Mennel R,et al.American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J Clin Oncol,2007,25(33):5287-5312.
  • 2Goldhirsch A,Wood WC,Gelber RD,et al.Progress and promise:highlights of the international expert consensus on the primary therapy of early breast cancer 2007.Ann Oncol,2007,18(7):1133-1144.
  • 3Hudis CA.Trastuzumab-mechanism of action and use in clinical practiee.N Engl J Med,2007,357(1):39-51.
  • 4Johnston S,Trudeau M,Kaufman B,et al.Phase Ⅱ study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.J Clin Oncol,2008,26(7):1066-1072.
  • 5Scahriti M,Rojo F,Ocana A,et al.Expression of p95 HER2,a truncated form of the HER2 receptor,and response to anti-HER2 therapies in breast career.J Natl Cancer Inst,2007,99(8):628-638.
  • 6Prit6hkrd KI,Shepherd LE,O'Malley FP,et al.HER2 and responsiveness of breast cancer to adjuvant chemotherapy.N Engl J Med,2006,354(20):2103-2111.
  • 7Gennari A,Sormani MP,Pronzato P,et al.nER2 status and efficacy of adjuvant anthraeye[!@s in early breast cancer:a pooled analysis of randomized trials.J Natl Cancer Inst,2008,100 (1):14-20.
  • 8Slamon D,Eiermann W,Robert N,et al.BCIRG 006:2nd interim analysis phase Ⅲ randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxoruhicin and cyclophosphamide followed by docetade[and trastuzumah(ACTH)with docetaxel,carboplatin and trastuzumah (TCH) in Her2neu positive early breast cancer patients.29th Annual San Antonio Breast Cancer Symposium,Deeember 14-17,2006.San Antonio,Texas,2006:A52.
  • 9Niskanen E,Blomqvist C,Franssila K,et al.Predictive value of c-erhB-2,p53,cathepsin-D and histology of the primary turnour in metastatic breast cancer.Br J Cancer,1997,76(7):917-922.
  • 10Hayes DF,Thor AD,Dressier LG,et al.HER2 and response to paclitaxel in node-positive breast cancer.N Engl J Med,2007,357(15):1496-1506.

共引文献3

同被引文献157

引证文献9

二级引证文献63

中华临床医师杂志（电子版）
2013年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部